Patents by Inventor Clifton E. Barry, III

Clifton E. Barry, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for the treatment of infectious diseases
    Patent number: 8268894
    Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: September 18, 2012
    Assignees: The United States of America as Represented by the Secretary, Department of Health and Human Services, Sequella, Inc.
    Inventors: Marina Nikolaevna Protopopova, Elena Bogatcheva, Leo Einck, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III
  • Compositions and methods for the treatment of infectious diseases
    Publication number: 20110118307
    Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.
    Type: Application
    Filed: November 11, 2010
    Publication date: May 19, 2011
    Inventors: Marina Nikolaevna PROTOPOPOVA, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III, Elena Bogatcheva, Leo Einck
  • Anti tubercular drug: compositions and methods
    Patent number: 7842729
    Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: November 30, 2010
    Assignees: The United States of America as represented by the Department of Health and Human Services, Sequella, Inc.
    Inventors: Marina Nikolaevna Protopopova, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III, Elena Bogatcheva, Leo Einck
  • Methods of diagnosing multidrug resistant tuberculosis
    Patent number: 7547519
    Abstract: The invention relates to the discovery that a putative gene of Mycobacterium tuberculosis with no previously identified function is responsible for the ability of the bacterium to activate thioamide drugs. Since M. tuberculosis has a low rate of synonymous mutations, all mutations in this gene, identified as Rv3854c and now termed “EtaA,” are expected to inhibit the ability of a bacterium with the mutation to activate a thioamide or thiocarbonyl drug. Thus, detecting a bacterium with a mutation in this gene indicates that the bacterium is resistant to treatment with thioamides.
    Type: Grant
    Filed: February 14, 2005
    Date of Patent: June 16, 2009
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Clifton E. Barry, III, Andrea E. DeBarber, Khisimuzi Mdluli, Linda-Gail Bekker
  • Anti tubercular drug: compositions and methods
    Patent number: 7456222
    Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: November 25, 2008
    Assignees: Sequella, Inc., The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Marina Nikolaevna Protopopova, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III, Elena Bogatcheva, Leo Einck
  • Methods of use and compositions for the diagnosis and treatment of infectious disease
    Patent number: 6951961
    Abstract: Methods and compositions for treating disease caused by microorganisms, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: October 4, 2005
    Inventors: Marina Nikolaevna Protopopova, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III
  • Methods of diagnosing multidrug resistant tuberculosis
    Patent number: 6905822
    Abstract: The invention relates to the discovery that a putative gene of Mycobacterium tuberculosis with no previously identified function is responsible for the ability of the bacterium to activate thioamide drugs. Since M. tuberculosis has a low rate of synonymous mutations, all mutations in this gene, identified as Rv3854c and now termed “EtaA,” are expected to inhibit the ability of a bacterium with the mutation to activate a thioamide or thiocarbonyl drug. Thus, detecting a bacterium with a mutation in this gene indicates that the bacterium is resistant to treatment with thioamides.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: June 14, 2005
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Clifton E. Barry, III, Andrea E. DeBarber, Khisimuzi Mdluli, Linda-Gail Bekker
  • Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated
    Patent number: 6403100
    Abstract: This invention provides for novel attenuated strains of Mycobacterium tuberculosis and M. bovis. Attenuation is achieved by eliminating or by downregulating the expression of the &agr;-crystallin heat shock protein gene (“acr gene”). The invention provides for vaccines and methods of vaccinating mammals for protection against Mycobacterium sp. that cause tuberculosis.
    Type: Grant
    Filed: June 27, 2000
    Date of Patent: June 11, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Clifton E. Barry, III, Ying Yuan, Deborah D. Crane
  • Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
    Patent number: 5610198
    Abstract: Compounds, pharmaceutical compositions, and methods for the treatment of mycobacterial diseases, such as tuberculosis and leprosy, are provided. Use of the compounds for promoting an antiseptic condition of a surface are also included. Some of the preferred compounds include thiatetracosanoic acids, esters, and fluorinated analogs.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: March 11, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Clifton E. Barry, III, Ying Yuan